ALSO NOTED: Ga. drug maker shuttered; Sirna raising $28M; Bavarian Nordic wins patent; and much more...

> The FDA has shut down Georgia drug maker Kiel Laboratories after citing it for numerous safety and quality violations. Story

> Sirna Therapeutics plans to raise $28 million through the sale of common stock. Release

> Bavarian Nordic has won a new patent for its MVA technology, a move that analysts believe will strengthen its chances of signing a big order of smallpox drugs with the US government. Report

> Human Genome Sciences of Rockville, Maryland, says a Phase II trial of HGS-ETR1 in combination with chemotherapy demonstrates sufficient results to warrant further study. Release

> Barr Laboratories has received full approval for a generic version of DDAVP Tablets. Release

> Emisphere Technologies of Tarrytown, New Jersey, has received its first milestone payment from a collaboration with Roche to develop new oral formulations of a Roche small molecule compound for the treatment of bone-related diseases. Release

> Canada's Advitech is touting positive results from a new study of XP-828L for treating psoriasis. Release

> Helix BioMedix of Bothell, Washington, says that new research shows that small bioactive peptides have the potential to attack two of the components responsible for the progression of lung damage in Cystic Fibrosis disease: infection and inflammation. Release

> Nastech Pharmaceutical of Bothell, Washington, has begun a Phase I trial with its intranasal Parathyroid Hormone (PTH1-34) to treat osteoporosis. Release

And Finally... USA Today looks at Massachusetts Gov. Mitt Romney's bid to require all state residents to obtain healthcare insurance. Article

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.